1: Song Z, Iorga BI, Mounkoro P, Fisher N, Meunier B. The antimalarial compound
ELQ-400 is an unusual inhibitor of the bc1 complex, targeting both
Qo and Qi sites. FEBS Lett. 2018 Apr;592(8):1346-1356.
doi: 10.1002/1873-3468.13035. Epub 2018 Mar 26. PMID: 29574797.
2: Chaudhry S, Zurbriggen R, Preza M, Kämpfer T, Kaethner M, Memedovski R,
Scorrano N, Hemphill A, Doggett JS, Lundström-Stadelmann B. Dual inhibition of
the Echinococcus multilocularis energy metabolism. Front Vet Sci. 2022
Aug 5;9:981664. doi: 10.3389/fvets.2022.981664. PMID: 35990276; PMCID:
PMC9388906.
3: McConnell EV, Bruzual I, Pou S, Winter R, Dodean RA, Smilkstein MJ,
Krollenbrock A, Nilsen A, Zakharov LN, Riscoe MK, Doggett JS. Targeted
Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo
Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome
bc1 and Identifies ELQ-400 as a Remarkably Effective Compound against
Acute Experimental Toxoplasmosis. ACS Infect Dis. 2018 Nov 9;4(11):1574-1584.
doi: 10.1021/acsinfecdis.8b00133. Epub 2018 Aug 30. PMID: 30117728; PMCID:
PMC6884402.
4: Stickles AM, Ting LM, Morrisey JM, Li Y, Mather MW, Meermeier E, Pershing AM,
Forquer IP, Miley GP, Pou S, Winter RW, Hinrichs DJ, Kelly JX, Kim K, Vaidya AB,
Riscoe MK, Nilsen A. Inhibition of cytochrome bc1 as a strategy for single-dose,
multi-stage antimalarial therapy. Am J Trop Med Hyg. 2015 Jun;92(6):1195-201.
doi: 10.4269/ajtmh.14-0553. Epub 2015 Apr 27. PMID: 25918204; PMCID: PMC4458825.
5: GC/MS • The ELQ-400 spectrEL® basic. Anal Chem. 1983 Feb 1;55(2):186A. doi:
10.1021/ac00253a755. PMID: 22742265.
6: Rufener R, Dick L, D'Ascoli L, Ritler D, Hizem A, Wells TNC, Hemphill A,
Lundström-Stadelmann B. Repurposing of an old drug: In vitro and in vivo
efficacies of buparvaquone against Echinococcus multilocularis. Int J Parasitol
Drugs Drug Resist. 2018 Dec;8(3):440-450. doi: 10.1016/j.ijpddr.2018.10.011.
Epub 2018 Oct 31. PMID: 30396011; PMCID: PMC6216040.